Get startedLog in
    Picture of Viking Therapeutics logo

    VKTX — Viking Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeLarge CapNeutral
    All News

    Brief: Viking Therapeutics Announces Initiation Of Phase 1 Study To Evaluate Novel Amylin Receptor Agonist Vk3019 In Healthy Adults

    Picture of Viking Therapeutics logoViking Therapeutics
    24/06/2026 12:27
    BRIEF-Viking Therapeutics Announces Initiation Of Phase 1 Study To Evaluate Novel Amylin Receptor Agonist Vk3019 In Healthy Adults
    June 24 (Reuters) - Viking Therapeutics Inc VKTX.O:
    • VIKING THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 STUDY TO EVALUATE NOVEL AMYLIN RECEPTOR AGONIST VK3019 IN HEALTHY ADULTS
    • VIKING THERAPEUTICS - EXPECTS TO REPORT VK2735 DOSING STUDY RESULTS IN 3Q26
    • VIKING THERAPEUTICS - TO INITIATE PHASE 3 TRIAL OF ORAL VK2735 LATER THIS YEAR
    Source text: ID:nPn1WpPSYa
    Further company coverage: VKTX.O

     ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Viking Therapeutics

    See all news